Rheumatoid Arthritis

Galapagos’ Oral Rheumatoid Arthritis Candidate Meets Primary Endpoint in Phase II Study

Belgium-based Galapagos NV said that its oral JAK1 inhibitor, in development for treatment of patients with rheumatoid arthritis (RA), met key endpoints in its mid-stage study. The company’s selective JAK1 inhibitor filgotinib showed improvements in signs and symptoms of active RA and met key efficacy endpoints after 12 weeks of …

Read More »

Catamaran Report Finds Drug Inflation and Increased Specialty Utilization Drives Increase in Drug Trend

Increased specialty utilization and drug inflation were the driving factors for overall drug trend more than doubling in 2014, according to a new report. Pharmacy Benefit Manager (PBM) Catamaran Corp. today released its annual Informed Trends report for 2014. Overall commercial drug trend was 5.7 percent in 2014, more than …

Read More »

Biogen’s Biosimilar Version of Remicade Accepted for Review by EMA

Biogen recently announced that European health regulators have accepted its biosimilar version of Remicade for review. The company said that the Marketing Authorization Application (MAA) for SB2, its biosimilar infliximab candidate using Remicade as a reference product, has been validated for review by the European Medicines Agency (EMA). The application …

Read More »

Lilly Partners with Hanmi for Autoimmune Disorder Drug

Eli Lilly and Company is shelling out up to $690 million for access to Hanmi Pharmaceutical’s Phase I compound HM71224, in development for autoimmune diseases. The companies announced today that they have entered into an exclusive license and collaboration agreement for the development and commercialization of Hanmi’s oral Bruton’s tyrosine …

Read More »

Galapagos and Janssen End Inflammation Alliance

Galapagos NV and Janssen Pharmaceutica NV of Johnson & Johnson have ended their eight-year alliance to develop anti-inflammatory drugs. The companies originally entered into a worldwide multi-target alliance in October 2007, to discover and develop novel small-molecule therapeutics for the treatment of rheumatoid arthritis (RA), a deal which provided Galapagos …

Read More »

Samsung Submits Application to the EMA for its Remicade Biosimilar Candidate, SB2

South Korea’s Samsung Bioepis Co., Ltd. recently announced that it has submitted a marketing authorization application (MAA) for SB2, its Remicade (infliximab) biosimilar candidate to European health regulators. The company said that it has submitted the MAA to the European Medicines Agency (EMA). The MAA for SB2 is the second …

Read More »